Skip to main content

Find Clinical Trials

Home
Conditions
Diabetes Mellitus, Insulin-Dependent, 12

Clinical trial condition

Diabetes Mellitus, Insulin-Dependent, 12

Explore clinical trials studying Diabetes Mellitus, Insulin-Dependent, 12. Study availability and eligibility vary by location and protocol.

57 public trials 8 recruiting studies

Refine in advanced search Browse all conditions

Diabetes Mellitus, Insulin-Dependent, 12 trial results

Not yet recruiting

GB268 Monotherapy or Combination Therapy for Locally Advanced/Metastatic Breast Cancer (Phase Ib/Ⅱ)

NCT07738341

Conditions: Breast Cancer (Locally Advanced or Metastatic), Breast Diseases, Breast Neoplasms, +9 more
Locations: Not specified

View Trial Details

Not yet recruiting

PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC

NCT07416058

Conditions: Adenocarcinoma, Adenocarcinoma of Lung, Carcinoma, +9 more
Locations: Not specified

View Trial Details

Not yet recruiting

Phase II Clinical Study on the Efficacy and Safety of the Combination of Cadonilimab and Capecitabine in Adjuvant Therapy for Combined Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma

NCT07243951

Conditions: Combined Hepatocellular-cholangiocarcinoma, Diabetes Mellitus, Insulin-Dependent, 12, Digestive System Diseases, +5 more
Locations: Not specified

View Trial Details

Not yet recruiting

A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma

NCT07131501

Conditions: Adenocarcinoma, CTLA-4, Carcinoma, +14 more
Locations: The First Affiliated Hospital with Nanjing Medical University Nanjing, Jiangsu, China

View Trial Details

Not yet recruiting

A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)

NCT07128251

Conditions: Adenocarcinoma, CTLA-4, Carcinoma, +14 more
Locations: Not specified

View Trial Details

Not yet recruiting

Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progression on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Prospective, Single-Arm, Exploratory Clinical Study

NCT07004335

Conditions: Advanced Melanoma, Bevacizumab, CTLA-4, +4 more
Locations: The Fourth Hospital of Hebei Medical University Shijiazhuang, China

View Trial Details

Not yet recruiting

A Phase I, First-in-Human Study of GB268 (PD-1/CTLA-4/VEGF Trispecific Antibody) in Advanced Solid Tumors

NCT06934616

Conditions: Diabetes Mellitus, Insulin-Dependent, 12, Solid Tumor Cancer
Locations: Not specified

View Trial Details

Active, not recruiting

A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors

NCT03530397

Conditions: Diabetes Mellitus, Insulin-Dependent, 12, Neoplasms, Selected Advanced Solid Tumors
Locations: Research Site Detroit, Michigan, United States

Research Site New York, United States

Research Site Chapel Hill, North Carolina, United States

Research Site Providence, Rhode Island, United States

View all 40 locations

View Trial Details

Active, not recruiting

A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC

NCT07000149

Conditions: Adenocarcinoma, Advanced Clear Cell Renal Cell Carcinoma, Carcinoma, +15 more
Locations: Research Site Elizabeth Vale, Australia

Research Site Busan, South Korea

Research Site Seoul, South Korea

View Trial Details

Active, not recruiting

Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma

NCT01843374

Conditions: Adenoma, Diabetes Mellitus, Insulin-Dependent, 12, Lung Diseases, +13 more
Locations: Research Site Scottsdale, Arizona, United States

Research Site La Jolla, California, United States

Research Site Los Angeles, California, United States

Research Site San Francisco, California, United States

View all 104 locations

View Trial Details